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Lipid metabolism is one of the HCV life cycle steps. HCV 
forms a replication complex in lipid raĞ  membrane that 
is full of cholesterol and sphingolipids.[6,7] 3-hydroxy-3 
methyl-glutaryl Coenzyme A inhibitors (statins) can 
reduce cholesterol level and fi nally can decrease HCV 
replication. Hence, statin therapy can be introduced as 
a complementary treatment.
In vitro examinations have found that some statins, 
especially fl uvastatin and atorvastatin can inhibit HCV 
replication,[8] although statins should be used with 
caution in advanced end-stage liver disease because of 
decompensation risk.[9]
Recently, benefi cial eﬀ ect of statin use among patients 
with HCV-related liver disease has been suggested. 
In vitro studies show that high concentrations of 
statins disrupt HCV replication through depletion of 
isoprenoid geranylgeranyl pyrophosphate.[10,11] Statins 
may thus have antiviral eﬀ ects through mechanisms 
not related to lipid metabolism.[12,13] The low-density 
lipoprotein (LDL) receptor and the high-density 
lipoprotein scavenger receptor B1 putatively facilitate 
INTRODUCTION
Hepatitis C virus (HCV) is an important human 
pathogen, not only because of its high prevalence and 
worldwide burden, but also because of the potentially 
serious complications of persistent HCV infection. 
These complications include cirrhosis, hepatocellular 
carcinoma, and end-stage liver disease necessitating 
liver transplantation. The incidence rates for all of 
these complications are expected to rise in the near 
future.[1,2]
It is estimated that 130-170 million people have chronic 
HCV (about 3% of the world population).[3,4] More than 
3,00,000 people die every year from hepatitis C related 
liver diseases.[5] There is no vaccination for HCV, so the 
treatment is very important.
The standard medication of HCV (pegylated interferon 
(IFN) alpha plus ribavirin [RBV]) in HCV genotype 
I infected patients have shown 40-50% sustained 
virological response (SVR),[3] so we need more eﬀ ective 
treatment method.
Background: Lipid metabolism is one of the hepatitis C virus (HCV) life cycle steps. Statins can reduce cholesterol level and 
ﬁ nally can decrease HCV replication. Th us, we assessed the eﬀ ect of Statins in combination with standard antiviral treatment on 
hyperlipidemic genotype I HCV infected patients. Materials and Methods: Th is study was a prospective clinical trial. 40 patients 
were selected from those referred to educational and Th erapeutic Centers of Isfahan University of Medical Sciences from 2009 
to 2010 with conﬁ rmed HCV viremia. All patients received Peg-interferon-a2a and ribavirin. 20 hyperlipidemic Patients received 
20 mg atorvastatin nightly for 3 months and placebo was prescribed for 20 normolipidemic HCV infected patients as a control 
group. Liver enzymes and complete blood count were checked monthly and thyroid stimulating hormone was checked every 
3 months. We also performed quantitative HCV-ribonucleic acid (RNA) test in 12th week of therapy, at the end of treatment and 
6 months after therapy for all samples. Results: We didn’t ﬁ nd any signiﬁ cant diﬀ erences in the mean of HCV-RNA numbers 
between statin and placebo groups in 12th week of treatment, in the end of treatment and 6 months after treatment (P > 0.05). 
Conclusion: Atorvastatin has no eﬀ ect on the mean of HCV viral load when we added it to standard treatment for hepatitis C 
infection. Further studies are necessary to examine the possible antiviral properties of statins and their potential role as adjuncts 
to standard HCV therapy.
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HCV entry into hepatocytes. Complex host proteins are 
found to be closely associated with HCV nonstructural 
proteins. The process which links these host and HCV 
proteins is termed prenylation. Statin agents which block 
the formation of the lipid precursors for prenylation, could 
theoretically interfere with viral replication.[14-16]
Some human studies have done for assessing the eﬀ ect of 
statins in hepatitis c treatment, but their results are diﬀ erent. 
O’Leary et al. have shown no reduction in HCV-ribonucleic 
acid (RNA) titers with 20 mg atorvastatin.[17] However, another 
study indicates non-dose-dependent discretion in HCV-RNA 
in %50 of patients,[18] the purpose of this study was to determine 
the eﬀ ect of statin therapy on standard antiviral treatment 
response in hyperlipidemic genotype I HCV patients .
MATERIALS AND METHODS
Selection of patient groups
Our study was a prospective clinical trial which was done 
on genotype I HCV patients who had been referred to 
educational and therapeutic centers of Isfahan University of 
Medical Sciences between years 2009 and 2010. All patients 
were tested to confi rm HCV viremia by Cobas Amplicor 
HCV Monitor test, version 2 (Roche Diagnostics, Mannheim, 
Germany). We selected our patients using simple random 
sampling. Subjects in the statin group were hyperlipidemic 
patients according to WHO defi nition for hyperlipidemia 
which is LDL cholesterol level more than 160 mg/dl, 130 mg/
dl for patient with one risk factor and 100 mg/dl for patients 
with diabetes mellitus, 2 or more than risk factors. Patients 
in the placebo group were selected from HCV patients 
without hyperlipidemia. This study protocol was approved 
by Institutional Review Board and Ethics CommiĴ ee of 
Isfahan University of Medical Sciences (research project 
number: 309079).
Patients were included in the study if they were naïve 
for HCV treatment, more than 18 years old and patients 
who did not have any clinical sign for decompensate 
Cirrhosis. All cases who were aﬀ ected by other genotypes 
of HCV and chronic liver disease such as hepatitis B virus, 
HIV, Wilson disease, hemochromathosis, autoimmune 
liver disease, primary biliary cirrhosis, secondary biliary 
cirrhosis, obstructive liver disease, viral infections that 
aﬀ ect liver function, and who had the history of alcohol 
drinking and drugs related steatosis and hepatotoxicity 
were excluded from our study. Patients were excluded 
from the study if the level of their liver enzymes (alanine 
transaminase and aspartate aminotransferase) had risen 
>3 times during statin treatment. Patients were examined 
clinically before antiviral treatment. Fasting blood sugar, 
plasma lipids, liver enzymes tests and liver and abdomen 
sonography (Hitachi, Tokyo Japan) were done 2 times (with 
1 month apart) before treatment for all of them. We also 
checked their blood pressure, waist size, and body mass 
index (BMI) according to related guideline.[19] All patients 
weekly received 180 μg Peg-IFN-a2a and 1000, 1200 and 
1400 mg RBV for weights <75 kg, 75-100 kg, and more than 
100 kg, respectively (Pegasys Co.). Statin group received 
20 mg atorvastatin (Farabi Co., Tehran, Iran) nightly for 
3 months and placebo was prescribed for the placebo group 
the same as atorvastatin in the statin group. Liver enzymes 
and complete blood count were checked monthly and 
thyroid stimulating hormone checked every 3 months. We 
also did quantitative HCV-RNA test to reveal patients with 
undetectable test in 12th week of therapy (early virological 
response [EVR]), aĞ er therapy (end of treatment virological 
response) and 6 months aĞ er therapy SVR for all samples.
We analyzed our data using SPSS version 16 (Inc., Chicago, 
IL, USA) and considered P < 0.05 as valuable, Chi-square 
was applied for comparison of categorical parameters and 
Student’s t-test for comparing the continuous parameters.
RESULT
Our study included 40 HCV positive patients (20 
hyperlipidemic and 20 normolipidemic patients). Our 
results showed that there are signifi cant diﬀ erences in the 
mean of BMI, triglyceride, LDL, and cholesterol between 
statin and placebo groups [Table 1].
The evaluation of viral load before statin therapy did not 
show a signifi cant diﬀ erence between statin and placebo, 
also, we didn’t fi nd any signifi cant diﬀ erences in the mean 
of HCV-RNA numbers in statin and placebo groups in 12th 
week of Statins therapy (P > 0.05), at the end of treatment 
(P > 0.05) and 6 months aĞ er treatment (P > 0.05) [Table 2]. 
Our fi ndings also implied that EVR in statin and placebo 
were 75 and 70% and SVR was 95% in both groups. ALT 
level was higher in statin group before treatment [Table 3]. 
Although both AST and ALT level rose aĞ er treatment, we 
did not fi nd any diﬀ erence between AST and ALT level 
aĞ er treatment.
Table 1: demographic and lipid character in statin and 
placebo group
Variable Mean ± SD P value
Statin group Placebo group
BMI 25.2±5.9 20.6±3 0.04
Cholesterol 249±17.6 206±24.7 <0.0001
TG (mg/dl) 306.9±71.6 168.5±32.7 <0.0001
HDL (mg/dl) 45.9±11.5 42.3±7.9 0.35
LDL (mg/dl) 189.5±13.7 129±20.6 <0.0001
Sex (male/female) 18/2 17/3 0.36
Age (year) 32±10 34.9±9.8 0.36
BMI = Body mass index; TG = Triglyceride; HDL = High-density lipoprotein; LDL = Low-
density lipoprotein; SD = Standard deviation
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DISCUSSION
In the current study, we didn’t find any significant 
diﬀ erences in the mean of viral load of hepatitis c in statin 
and placebo groups in 12th week of statin therapy, at the end 
of treatment and 6 months aĞ er treatment. Our fi ndings 
also implied that early response to treatment (EVR) in 
statin and placebo were 70 and 75% and Sustain response 
to treatment (SVR) in statin and placebo was 95% in both 
groups.
A pilot study of 31 HCV-infected veterans who were 
given fluvastatin 20-320 mg/day for 2-12 weeks with 
weekly monitoring of HCV-RNA and liver tests reported 
modest reductions of viral load.[20] Furthermore, a 
pharmacoepidemiologic study found that the use of 
lovastatin was associated with a 40-50% lower incidence 
of moderate as well as severe liver injury among patients 
with preexisting liver disease.[21]
Even though, prior individual studies examined 
important aspects of the association between statin and 
lowering the severity if liver disease in HCV-infected 
patients, these studies either did not adjust for histological 
severity of liver disease, had generally short follow-up, or 
did not use placebo subjects. Clearly, more information 
is needed about the possible benefi cial eﬀ ect of statins in 
HCV-infected.[22]
The result of other in vivo studies has been same as our 
fi ndings in this study. A study which has done by O’Leary 
et al. (2007) on 10 samples show that atorvastatin does not 
inhibit HCV-RNA replication in vivo.[17] Forde et al. in a 
cross-sectional study (2009) confi rmed that statins don’t 
have any apparent eﬀ ect on HCV-RNA replication in vivo.[23]
Unlike in vivo studies the result of in vitro research has shown 
that statins can decrease HCV-RNA replication.[3] Ikeda et al. 
evaluated the eﬀ ect of statins on HCV-RNA replication in 
OR6 cells.[24] Fluvastatin exhibited the strongest anti-HCV 
activity while atorvastatin and simvastatin showed 
moderate inhibitory eﬀ ects. The combination of IFN and 
the statins exhibited strong inhibitory eﬀ ects on HCV-RNA 
replication.[25,26]
There are some reasons for diﬀ erences between in vitro and 
in vivo studies. As we told before various factors aﬀ ect on 
antiviral treatment response in the human body such as 
obesity, insulin resistance and liver steatosis[15,16] so we need 
to do more studies to examine the eﬀ ect of statins on HCV 
in relation to confounder factors. On the other hand, statins 
concentration in cell cultures is higher than their concentration 
in plasma. Studies have shown that serum levels of such 
agents aĞ er prolonged therapy are signifi cantly lower than the 
statin concentrations those were used in replicon systems.[27]
In our study, response rate of patients were higher than 
western studies, there are some similar reports that show 
high response rate of combination therapy in Iranian 
patients, it may be due to lower viral load in comparison 
to western patients.[28,29]
In summary in our study statins did not have any signifi cant 
eﬀ ect on HCV virus number and virologic response. Our 
limitation in this study was few sample size, and further 
studies are necessary to examine the possible antiviral 
properties of statins and their potential role as adjuncts to 
standard HCV therapy.
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